Answers are grounded in this paper and cite their sources.
Among participants with chronic HBV infection who had virologic suppression with NA therapy, treatment with xalnesiran plus an immunomodulator resulted in HBsAg loss at 24 weeks after the end of treatment in a substantial percentage of participants. Grade 3 or 4 adverse events were not uncommon. (Funded by F. Hoffmann-La Roche; Piranga ClinicalTrials.gov number, NCT04225715.).
No takes yet. Share an insight, caveat, or question.
Hou et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: